With a unique heritage in dermatology as well as decades of cutting-edge innovation, Galderma is the leading company solely dedicated to advancing dermatology for every skin story. We are strategically positioned in attractive, consumer-driven segments of the dermatology market, characterized by high growth fundamentals. Through trusted partnerships with healthcare professionals, we ensure to meet individual consumer and patient needs with superior outcomes.
KEY FACTS ABOUT GALDERMA
3.760 B USD
2022 net sales
4
manufacturing sites
Global presence
we operate from 50 sites in 40 countries, with our headquarters in Switzerland
620+
clinical trials funded across 30+ countries since 2020
131
major health authority approvals since 2020
100,000+
aesthetics healthcare professionals trained via our Global Aesthetic Injector Network (GAIN) program in 2022
LEADERSHIP
Find out about our leadership team by clicking here.
A timeline of our history
1981
Foundation of Galderma as a joint venture between L’Oréal and Nestlé
Following the invention of the first Cetaphil formulation in 1947
1984
Galderma discovers Adapalene
1986
First commercial operations
1995
Launch of Differin for acne treatment
2000
Opening of our production site in Baie d’Urfé, Canada
2001
Licensing agreement for Metvix (Skin cancer)
2004
Opening of our production site in Hortolândia, Brazil
2007
Launch of Differin 0.3%
2008
Launch of Epiduo
2009
Launch of Azzalure and Restylane Injector
